贝伐珠单抗联合铂类化疗药物治疗中晚期NSCLC的近期疗效及安全性

Short term efficacy and safety of bevacizumab combined with platinum chemotherapy drugs in the treatment of advanced NSCLC

目的探究贝伐珠单抗联合铂类化疗药物治疗中晚期非小细胞肺癌(NSCLC)的近期疗效及安全性。方法选择我院2021年1月~2022年12月收治的86例中晚期NSCLC患者作为研究对象,根据治疗方案不同分为对照组和联合组,各43例。对照组采用铂类药物化疗,联合组在铂类药物化疗的基础上联合应用贝伐珠单抗,治疗3个疗程后,对比两组的疗效以及治疗相关不良反应发生情况。结果治疗3个疗程后,联合组临床获益率明显高于对照组,差异有统计学意义(P<0.05)。治疗后,两组血清CEA、CYFRA21-1水平以及KPS评分均较治疗前有改善,且联合组血清CEA、CYFRA21-1水平明显低于对照组,KPS评分显著优于对照组,差异有统计学意义(P<0.05)。两组治疗期间发热、胃肠道反应、肝功能损伤、白细胞减少、血小板减少的发生率对比无明显差异(P>0.05)。结论贝伐珠单抗联合铂类化疗药物治疗中晚期NSCLC能够提高近期疗效,控制患者血清肿瘤标志物水平和改善其生存质量,且不会增加不良反应。

Objective To explore the short-term efficacy and safety of bevacizumab combined with platinum-based chemotherapy drugs in the treatment of advanced non-small cell lung cancer(NSCLC).Methods 86 patients with advanced NSCLC in our hospital were selected as study objects from January 2021 to December 2022.They were divided into the control group and the combined group with 43 cases in each group according to different treatment regimens.The control group received platinum-based chemotherapy,while the combined group received bevacizumab in addition to platinumbased chemotherapy.After 3 treatment cycles,the patients'curative effect,the occurrence of treatment-related adverse reaction were compared between the two groups.Results After 3 cycles of treatment,the clinical benefit rate of the combined group was significantly higher than the control group(P<0.05).After treatment,serum CEA,CYFRA21-1 levels and KPS score in the two groups were improved compared with before treatment,serum CEA and CYFRA21-1 levels in the combined group were significantly lower than the control group,and KPS score in the combined group was significantly better than the control group(P<0.05).There were no significant differences in the incidence of fever,gastrointestinal reaction,liver damage,leukopenia and thrombocytopenia between the two groups during treatment(P>0.05).Conclusion Bevacizumab combined with platinum-based chemotherapy can improve short-term efficacy in the treatment of advanced NSCLC,control serum tumor marker levels and improve the quality of life of patients,without increasing adverse reaction.